Description: BNC Korea Co., Ltd. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj., temporary reduce glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity; Juvegel, temporary reduce nasolabial folds in adults; Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia; HA fillers and skin booster fillers, including Cutegel, Cutegel Lidocaine, FLORE Lidocaine, CUTEGEL-M, Cutegel Hydro, S-DNA, and H-DNA, which are used to temporarily reduce facial wrinkles through physical restoration. It also provides Hibarry, a bio-absorbable gel and solution mixture used to prevent adhesion of the spinal cord post-surgery; GENTA Q, a white collagen sponge, which is used to protect deep cavity wounds such as surgical sites from contamination; and care, beauty face, repair hydrogen masks, mild cleansing foams, and brightening peeling gels. The company also exports its products to 45 countries. BNC Korea Co., Ltd. was founded in 2007 and is headquartered in Daegu, South Korea.
Home Page: www.bnckorea.co.kr
#405, Structure 1
Daegu,
South Korea
Phone:
82 70 7116 0059
Officers
| Name | Title |
|---|---|
| Mr. Wan-Gyu Choi | Chief Executive Officer |
Exchange: KQ
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.3088 |
| Price-to-Sales TTM: | 3.3479 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 193 |